• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Important Product Information - Correction - Corzyme-Abbott Laboratories



February 18, 2005


List Number 9977
All Lots




Abbott Laboratories
Abbott Park, IL


Abbott Laboratories recently completed a study comparing an internally produced anti-HBc dilution panel (Panel) used in product testing against a reference serum provided by the Paul-Erhlich-Institut (PEI, Germany). This Panel is used to determine the CORZYME Positive Control anti-HBc concentration expressed in PEI Units/mL. The results of the study revealed differences in PEI Units/mL of the anti-HBc dilution panel as compared to a reference serum from the Paul Erhlich-Institut. As a result of this difference, concentrations expressed in PEI Units/mL are inaccurate.


The CORZYME Positive Control Human anti-HBc concentration in PEI Units/mL will no longer be provided. In addition, the PEI reference range statement in the CORZYME Package Insert (66-6633/R17) will be removed in the next revision of the CORZYME Package Insert. Consignees have been asked to place a copy of their "Important Product Information Letter" with any remaining CORZYME kit inventory.



Contact FDA

(800) 835-4709
(301) 827-1800
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

1401 Rockville Pike

Suite 200N/HFM-47

Rockville, MD 20852-1448